Technical Analysis for ADXS - Advaxis, Inc.

Grade Last Price % Change Price Change
grade D 1.02 -4.67% -0.05
ADXS closed down 4.67 percent on Thursday, February 20, 2020, on approximately normal volume. Its advance stalled at its 200 day moving average, an important long-term support / resistance line.
Earnings due: Mar 10
*** please verify all earnings dates ***

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Up Flat
Historical ADXS trend table...

Date Alert Name Type % Chg
200 DMA Resistance Bearish 0.00%
Wide Bands Range Expansion 0.00%
200 DMA Resistance Bearish -4.67%
NR7 Range Contraction -4.67%
Inside Day Range Contraction -4.67%
Wide Bands Range Expansion -4.67%
200 DMA Resistance Bearish -2.86%
Wide Bands Range Expansion -2.86%
Wide Bands Range Expansion 0.99%
200 DMA Resistance Bearish -1.92%

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Advaxis, Inc., a clinical development stage biotechnology company, engages in the development of immunotherapies for cancer and infectious diseases. The company's platform technology generates an immune response by serving as its own adjuvant, directing antigen presentation, increasing tumor infiltrating killer T-cells, and decreasing Tregs/MDSCs in the tumor. It has approximately 15 distinct constructs in various stages of development, directly developed by the company and through strategic collaborations. The company's products in clinical development stage include ADXS-HPV that is being evaluated in clinical trials for cervical cancer, CIN 2/3, head and neck cancer, and anal cancer. Its products in clinical development stage also comprise ADXS-PSA for prostate cancer; and ADXS-cHER2 for overexpressing cancers, such as breast, gastric, and other cancers in humans, as well as for osteosarcoma in canines. The company was founded in 2002 and is based in Princeton, New Jersey.
Medicine Biotechnology Cancer Infectious Diseases Cancers Prostate Cancer Tumor Immunotherapies Infectious Causes Of Cancer Platform Technology Head And Neck Cancer Cancer Vaccine Human Papillomavirus Infection Osteosarcoma Cervical Cancer Anal Cancer

Is ADXS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 10.8
52 Week Low 0.2051
Average Volume 7,812,379
200-Day Moving Average 1.06
50-Day Moving Average 0.92
20-Day Moving Average 0.94
10-Day Moving Average 1.02
Average True Range 0.13
ADX 21.45
+DI 28.82
-DI 19.93
Chandelier Exit (Long, 3 ATRs ) 0.86
Chandelier Exit (Short, 3 ATRs ) 1.05
Upper Bollinger Band 1.16
Lower Bollinger Band 0.72
Percent B (%b) 0.69
BandWidth 47.39
MACD Line 0.03
MACD Signal Line 0.03
MACD Histogram 0.0073
Fundamentals Value
Market Cap 41.89 Million
Num Shares 41.1 Million
EPS -2.29
Price-to-Earnings (P/E) Ratio -0.45
Price-to-Sales 9.06
Price-to-Book 1.70
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.17
Resistance 3 (R3) 1.18 1.14 1.15
Resistance 2 (R2) 1.14 1.10 1.14 1.14
Resistance 1 (R1) 1.08 1.08 1.06 1.07 1.13
Pivot Point 1.04 1.04 1.03 1.04 1.04
Support 1 (S1) 0.98 1.00 0.96 0.97 0.91
Support 2 (S2) 0.94 0.98 0.94 0.90
Support 3 (S3) 0.88 0.94 0.90
Support 4 (S4) 0.87